Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent Biosolutions (NY: EBS )

7.570 +0.790 (+11.65%)
Official Closing Price Updated: 4:10 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,434,357
Open 6.790
Bid (Size) 7.690 (2)
Ask (Size) 7.850 (1)
Prev. Close 6.780
Today's Range 6.270 - 7.720
52wk Range 1.420 - 15.10
Shares Outstanding 52,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
WHO Declares Mpox Public Health Emergency: 'Coordinated International Response Essential' To Halt Outbreak
A public health emergency for mpox in Africa saw vaccine stocks jump Wednesday. A look at the stocks and what's next for fighting the virus. 
Via Benzinga
Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks
Emergent BioSolutions reported Q2 2024 sales of $254.7 million, beating estimates but showing a 25% decline year-over-year. Despite a significant adjusted EPS loss and mixed performance across product... 
Via Benzinga

Performance

YTD
+192.28%
+192.28%
1 Month
-33.07%
-33.07%
3 Month
+49.02%
+49.02%
6 Month
+376.10%
+376.10%
1 Year
+37.89%
+37.89%

More News

Read More
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Key Takeaways From Emergent BioSolutions Analyst Ratings
Via Benzinga
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Emergent BioSolutions (EBS) Q2 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Emergent BioSolutions Reports Second Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
From Emergent BioSolutions
Via GlobeNewswire
8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%
Via Benzinga
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
How To Earn $500 A Month From American Express Stock Ahead Of Q2 Earnings
Via Benzinga
Watch These 4 Overbought Stocks As Market Rotation Continues
Via MarketBeat
Topics ETFs
How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings
Via Benzinga
Johnson & Johnson Faces MedTech Challenges But Is 'On Track' To Meet 2024 Guidance: Goldman Sachs
Via Benzinga
Emergent BioSolutions And Johnson & Johnson Resolve Claims Over COVID-19 Vaccine Manufacturing
Via Benzinga
Exposures COVID-19
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
From Emergent BioSolutions
Via GlobeNewswire
Why Is Vaccine Maker Emergent BioSolutions Stock Trading Higher On Tuesday?
Via Benzinga
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
7 Top Stocks Under $10: June 2024 Edition
Via InvestorPlace
What Is Going On With Emergent BioSolutions Shares?
Via Benzinga
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million
From Emergent BioSolutions
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.